28.07.2005 – 10:11

Zeltia Group

Zeltia S.A.: Report at 30 June 2005

Madrid (ots/PRNewswire)

PharmaMar:

• Orphan Drug designation granted by the FDA to Yondelis for the treatment of ovarian cancer in April.
• Patient recruitment ongoing for the Phase III trial of Yondelis in ovarian cancer.
• Promising results of Phase II trial of Yondelis in prostate cancer released at ASCO.
• PharmaMar received 1 million dollars for complying with a milestone under the licensing and co-development contract with Johnson & Johnson.
• Patient enrolment goal reached in the Phase II study of Yondelis in STS

Other:

• Zeltia increased capital, raising 65 million euro.
• Group revenues amounted to 39 million euro.
• The net cash position (cash + cash equivalents - short-term bank debt) amounted to 115 million euro.

For further information please refer to www.zeltia.com

Isabel Lozano
    CEO
    PharmaMar, S.A..U.
    C/ Reyes, 1. Colmenar Viejo
    Madrid
    Telephone: +34-91-846-60-00
    Catherine Moukheibir
    Head of Capital Market
    Strategy
    Zeltia, S.A.
    José Abascal, 2. Madrid
    Telephone: +34-91-444-45-00
    Ma Luisa de Francia
    CFO
    Zeltia, S.A.
    José Abascal, 2. Madrid
    Telephone: +34-91-444-45-00

Contact:

Isabel Lozano, CEO, PharmaMar, S.A..U., C/ Reyes, 1. Colmenar Viejo,
Madrid, Telephone: +34-91-846-60-00; Catherine Moukheibir, Head of
Capital Market, Strategy, Zeltia, S.A., José Abascal, 2. Madrid,
Telephone: +34-91-444-45-00; Ma Luisa de Francia, CFO, Zeltia, S.A.,
José Abascal, 2. Madrid, Telephone: +34-91-444-45-00